BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 22, 2005
View Archived Issues
Salivary bacteria species predict oral squamous cell carcinoma
Read More
Hydroxyurea reduces vascular event risk more than anagrelide in essential thrombocythemia
Read More
Gene therapy-induced angiogenesis shows promise for treating cardiovascular disease
Read More
Erlotinib lengthens survival in previously treated non-small cell lung cancer
Read More
Aphios collaborates with Japanese companies on paclitaxel prodrug
Read More
Epix Pharmaceuticals to amend phase II protocols for EP-2104R
Read More
CX-3543 begins phase I cancer trial
Read More
Encouraging early data from phase I/II study of AV-201 for Parkinson's disease
Read More
HIV protease inhibitor 640385 receives fast track designation
Read More
Hemospan begins new phase II surgical blood loss trial
Read More
Phase III program studies tenofovir disoproxil fumarate for chronic hepatitis B
Read More
FDA requests more information to complete NE-180 IND review
Read More
InterMune and Array BioPharma expand HCV collaboration
Read More
Alkermes and Lilly begin phase III study of inhaled insulin system
Read More
Novartis receives U.S. clearance to complete acquisition of Eon Labs
Read More
New phase II trial for Imvamune in HIV patients
Read More
Genzyme launches minimal residue disease test for B-CLL
Read More
Toyama Chemical begins U.S. phase I study of T-817MA
Read More
Celecoxib reported safe when given to NSCLC patients on thoracic radiotherapy
Read More
Update on the antitumor effects of Xyotax in NSCLC
Read More
Phase II data show OSI-211 not effective enough in recurrent small cell lung cancer
Read More
L-BLP-25 improves survival in advanced NSCLC patients
Read More
Structure disclosed for TPI-287
Read More
Mitsubishi launches argatroban as first solely marketed product in Europe
Read More
Novel cannabinoid CB1/CB2 receptor modulators emerge from Solvay R&D
Read More
Therapeutic agents for hepatitis C infection claimed
Read More